Clinical Trial RESULTS
Clinical Trial
RESULTS
Research Sponsor: Ardea Biosciences, Inc.
Drug Studied: RDEA3170
Study Drug Indication: Gout
National Clinical Trial #: NCT02498652
Protocol #: RDEA3170-206
Study Date: July 2015 to November 2015
Short Study Title: A study in participants with gout to determine if
RDEA3170, when taken with allopurinol daily,
will further reduce uric acid in the blood.
Thank you!
As a clinical study participant, you belong to a large community of participants around
the world. You help researchers answer important health questions and discover new
medical treatments.
Thank you for taking part in the clinical study for the study drug RDEA3170.
RDEA3170 is a new drug being developed to treat gout, a type of arthritis.
You and all of the participants helped researchers learn if RDEA3170 together with another
drug called allopurinol can treat gout.
Ardea Biosciences, Inc., the sponsor of this study, thanks you for your help and thinks
it is important for you to know the results of your study. An independent non-profit
organization called CISCRP prepared this summary of the study results for you with the
help of a medical writing organization. We hope it helps you understand and feel proud of
your important role in medical research. If you have questions about the results, please speak
with the doctor or staff at your study site.
11